Andere talen Biosergen AB

Aandelen

BIOSGN

SE0016013460

Beurs gesloten - Nasdaq Stockholm Andere beurzen 15:39:32 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,346 ^SEK	+3,59%		+1,47%	-60,68%

09/04	Biosergen geeft nieuwe eenheden uit als compensatie in het kader van claimemissie	MT
27/03	Biosergen haalt 26,4 miljoen Zweedse kronen op via claimemissie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Conversion of paid subscribed units and first day of trading with warrants of series TO3	16/04
Biosergen to Issue New Units as Compensation Under Rights Issue	09/04
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue	09/04
Biosergen Raises SEK26.4 Million via Rights Issue	27/03
Biosergen announces the outcome in the rights issue	26/03
BioStock Investor Pitch: Biosergen	18/03
Members of the board of directors and management subscribe in ongoing rights issue	15/03
Research update Biosergen: Rights issue to fund crucial step for lead project	13/03
BioStock: Rights issue to give Biosergen first in-human efficacy data	12/03
BioStock: Biosergen attacks invisible threat of fungal infections	08/03
Carlsquare Equity Research interview with Biosergen	07/03
Biosergen CEO to BioStock: "Positive data give us a strong value proposition"	07/03
Biosergen publishes prospectus due to rights issue of units	05/03
Bulletin from the extraordinary general meeting in Biosergen AB (publ)	01/03
Biosergen publishes interim report for fourth quarter 2023	29/02
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	12/02
Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.	12/02
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	12/02
Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step	02/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Biosergen AB

Aandelen

BIOSGN

SE0016013460

Andere talen

Filters